CRISPR Therapeutics reported positive Phase 1 results from its in vivo CRISPR/Cas9 candidate CTX310 targeting ANGPTL3. At the highest administered dose, patients achieved mean decreases of 73% in ANGPTL3 (peak 89%), 55% in triglycerides (peak 84%) and 49% in LDL cholesterol (peak 87%) after a single intravenous infusion. In the subgroup with baseline triglycerides above 150 mg/dL, mean reductions reached 60%. No treatment-related serious adverse events or Grade 3+ liver transaminase elevations were observed, supporting CTX310’s safety and durability profile and justifying advancement into Phase 1b trials focused on severe hypertriglyceridemia and mixed dyslipidemia.

Casgevy, the company’s ex vivo CRISPR-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, holds the only approved product designation in CRISPR Therapeutics’ portfolio. After achieving freedom from vaso-occlusive crises for a full year in pediatric Phase 3 CLIMB-151 and transfusion independence in CLIMB-141, the commercial launch has been gradual. Management forecasts a material uptick in patient enrollments and product shipments through 2026 as additional treatment centers come online, payer coverage expands and the Priority Review Voucher accelerates global filings. These factors are expected to drive the first significant revenue contribution for the company next year.

Beyond CTX310 and Casgevy, CRISPR Therapeutics maintains a broad pipeline spanning in vivo cardiovascular, CAR-T oncology and metabolic disease programs. Early-stage candidates include CTX900 for hemoglobinopathies and CTX1502 for solid tumors, each leveraging the Cas9 platform. The company’s manufacturing partnerships and vector delivery improvements underpin its 17.9% projected compound annual growth rate in cell and gene therapy capacity through 2034. Investors view this diversified pipeline—combined with CTX310’s proof of concept and Casgevy’s commercial launch—as key upside drivers to the current $5 billion enterprise valuation.